In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe

Pharmaceutical Technology

In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers.

ManufacturingRead full story